Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 – Full Year 2020 Year-Over-Year: – Product Sales increased 10% to $24.4 billion, primarily due to Veklury – – Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 – – Returned $5.0 billion of cash to shareholders through dividends and share repurchases – Full Year 2021 Guidance: – Product Sales including Veklury of $23.7 billion to $25.1 billion – �...
United States Foster City Jacquie Ross Sonoma Biotherapeutics Ledipasvir Sofosbuvir Sofosbuvir Velpatasvir
Source: investingnews.com